AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 251 min read$RVTY

Revvity (NYSE: RVTY) director donates 285 shares in stock gift

Revvity (NYSE: RVTY) director Alexis P. Michas reported a gift of 285 shares of common stock by The Cayre and Alexis Michas Foundation Corp. to a charity. Post-transaction, the foundation holds 6,985 shares indirectly, Michas holds 63,780 shares directly, and a spouse IRA holds 500 shares indirectly. Michas disclaims beneficial ownership of the foundation-held shares except for pecuniary interest.

Original reporting
stocktitan.net
Published Aug 25, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 8:59 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$RVTY
Neutral
high confidence
Mentioned
$RVTY
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$RVTYNeutralLow
01

Why it matters

The disclosed gift does not alter Revvity's share count or ownership distribution in any material way.

02

Market read

Minimal relevance; the filing is a routine insider disclosure with negligible market impact.

03

What to watch

The director's large existing stake (over 63,000 shares) means the gift represents less than 0.5% of his holdings, limiting any signaling effect.

Relevance 4/10Novelty 2/10Timing: 2026-08-25

Background

Form 4 filings disclose insider transactions; gifts are reported at zero value and are often tax‑driven charitable contributions.

Company-level read

Ticker impact

$RVTYNeutralHigh confidence
Context

Director Alexis P. Michas reported a Form 4 gift of 285 Revvity shares to a charitable organization on 2026-08-25.

Expected impact

No material price impact expected.

Evidence & confidence

The transaction size is negligible relative to total holdings and market float; insider gifts of this magnitude are routine and rarely move the stock.

Market effects

Sector

No broader sector impact; Revvity operates in medical diagnostics, a sector unaffected by a small insider gift.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even small insider gifts can signal confidence, but the size here is too trivial to infer any meaningful sentiment.

Key entities

  • Director
    Alexis P. Michas

    Director of Revvity who made the gift.

  • Company
    Revvity, Inc.

    Medical diagnostics company (NYSE: RVTY).

Read at source← All news

Related articles

SEP 1
$RVTYMed

RBC Capital initiates Revvity stock with Sector Perform rating

RBC Capital initiated coverage on Revvity Inc. (NYSE:RVTY) with a Sector Perform rating and a $135 price target. The stock trades near its 52-week high after a 31% surge over six months. RBC cited durable franchises but noted structural challenges to growth. Revvity's P/E ratio is 61, and it is considered overvalued. The company reported Q2 earnings and revenue above expectations, driven by organic growth and AI demand. Stifel raised its price target to $110 but maintained a Hold rating.

investing.com2 min
AUG 31
$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

rttnews.com2 min
AUG 11
$RVTYHighAI 9/10

Revvity (RVTY) Q2 2026 Earnings Call Transcript

Revvity (RVTY) reported Q2 2026 pro forma revenue of $711 million, up 3% organically, and pro forma adjusted EPS of $1.41. Diagnostics revenue rose 11% organically, while Signals software declined 20% organically. Free cash flow was $184 million. Full-year organic growth guidance was raised to 4% to 5% and adjusted EPS to $5.30 to $5.40.

fool.com7 min
AUG 9
$RVTYMedAI 8/10

Revvity Q2 Earnings Call Highlights

Revvity (RVTY) reported Q2 results on an earnings call, with Diagnostics revenue of $352M up 12% reported and 11% organic. Life Sciences revenue was $359M, down 2% reported and 3% organic, driven by a ~20% Signals software decline. For 2026, it raised pro forma organic growth to 4%-5% and guided revenue $2.83B-$2.86B, adjusted EPS $5.30-$5.40. It expects Q3 revenue $685M-$700M and organic growth 4%-6%.

finance.yahoo.com6 min
AUG 6
$RVTYMed

Revvity, Inc. Q2 2026 Earnings Call Summary

Revvity, Inc. reported Q2 2026 results, citing improving pharma and biotech spending and higher orders tied to AI-driven drug discovery. Management said Opera Phenix OptIQ demand outpaces capacity, raised full-year organic growth guidance to 4% to 5%, and expects Signals software double-digit growth in H2. It signed an agreement to divest China immunodiagnostics and targets gross leverage below 3x by year-end.

yahoo.com6 min
AUG 5
$RVTYMedAI 8/10

Why Revvity (RVTY) Stock Is Up Today

Revvity (NYSE: RVTY) shares rose about 3% after the company reported Q2 2026 adjusted EPS of $1.41 versus $1.21 expected, and revenue of $729.68 million versus $703.39 million. Revvity lifted full-year guidance to 4% to 5% organic growth and EPS of $5.30 to $5.40. Stifel raised its target to $110 and Bernstein to $120.

financialcontent.com4 min